TerzaPowerApplicator Pen · 20 mg / 3 ml
Dual GIP and GLP-1 receptor agonist in an Applicator Pen format (20 mg / 3 ml) for weekly weight management, metabolic balance and glycemic control
Two pathways. One result
Tirzepatide activates both GIP and GLP-1 receptors at once — unlike GLP-1 monotherapy, this delivers an additive metabolic effect.
GIP receptor
Boosts insulin secretion by beta cells and improves tissue insulin sensitivity.
GLP-1 receptor
Suppresses glucagon, slows gastric emptying and reduces appetite via central mechanisms.
Synergy of dual agonism
A comprehensive effect on body weight, glycemia, lipids and blood pressure.
Results proven in trials
Key effects
Comprehensive metabolic impact through the dual GIP / GLP-1 mechanism of action
Weight loss up to 20–22%
Glycemic control (HbA1c)
Appetite reduction
Improved lipid profile
Blood pressure reduction
Insulin sensitivity
Reduced hepatic steatosis
Lower inflammation markers
Gradual titration
The pen sets the dose by combining fixed 2.5 and 5 mg steps. Standard once-weekly schedule:
7.5 and 12.5 mg are optional steps. The titration schedule and dose selection are determined by the physician. 15 mg is the maximum dose.
How it works TerzaPower
- Dual activation of GIP and GLP-1 receptors in the GI tract and the brain
- Enhanced glucose-dependent insulin secretion by beta cells
- Suppression of glucagon secretion and hepatic glucose production
- Slowed gastric emptying — prolonged satiety
- Reduced appetite and food cravings via central mechanisms
- Increased peripheral insulin sensitivity and adipocyte metabolism
Why TerzaPower Pen?
How is TerzaPower Pen different from other GLP-1 agonists?
Unlike GLP-1 monotherapy, TerzaPower activates both GIP and GLP-1 receptors — two independent metabolic pathways. In a head-to-head trial (SURMOUNT-5, NEJM 2025) tirzepatide achieved 20.2% weight loss versus 13.7% for semaglutide.
What is the format and how is TerzaPower Pen dosed?
It is a multi-dose pen with a pre-installed 20 mg / 3 ml cartridge (ready solution, no reconstitution needed). The pen has two fixed dose steps — 2.5 mg and 5 mg.
Standard titration schedule:
- Weeks 1–4: 2.5 mg once weekly (starting dose)
- Weeks 5–8: 5 mg once weekly
- Weeks 9–12: 7.5 mg (optional)
- Weeks 13–16: 10 mg once weekly
- Weeks 17–20: 12.5 mg (optional)
- Week 21+: 15 mg once weekly — maximum dose
Intermediate / higher doses are set by combining the 2.5 and 5 mg steps per the physician's schedule. Administered subcutaneously once weekly (abdomen, thigh or upper arm), independent of meals.
Which patients is TerzaPower Pen suitable for?
For adult patients (≥18 years):
- Chronic weight management: BMI ≥30 kg/m², or BMI ≥27 kg/m² with a comorbidity (hypertension, dyslipidemia, T2D, sleep apnea)
- Type 2 diabetes — adjunct to diet and physical activity
- Moderate-to-severe obstructive sleep apnea in obesity
Prescribed strictly on a physician's indication.
How should TerzaPower Pen be stored?
Store at 2–8 °C in the main compartment of the refrigerator (not in the door, not in the freezer), in the original packaging for light protection. Outside the refrigerator — up to 30 °C, no more than 21 days in total. Freezing is prohibited. Shelf life: 24 months (unopened), 30 days after first use.
What are the side effects and contraindications?
The most common side effects are gastrointestinal (nausea, diarrhea, vomiting, constipation), are dose-dependent and usually resolve within 4–8 weeks with gradual escalation.
Absolute contraindications: personal or family history of medullary thyroid carcinoma (MTC), MEN2 syndrome, hypersensitivity to tirzepatide, pregnancy. Full list in the clinical protocol.
What to do about a missed dose?
If ≤4 days (96 h) have passed — administer the dose as soon as possible, then return to the usual schedule. If >4 days have passed — skip the dose and resume on the next scheduled day. A double dose is prohibited; there must be ≥3 days (72 h) between doses.
Request TerzaPower Pen
Leave your details — a manager will contact you about terms, availability and partnership.
For professional use only, under the supervision of a qualified specialist. This information is not a public offer or a substitute for medical advice.
Request product
International ecosystem and scientific environment worldwide
Representations
Sportyvna Square, 1a, Kyiv, 01023
International representations:
80 Sand Island Access Road Unit 238, Honolulu HI USA 96819
105 Yanghwa-ro, Mapo-Gu, Seoul, South Korea
Contact us
Phone: +380 (99) 811 68 37
truemed.ukraine@gmail.com
